<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer-Verlag</PublisherName>
    <PublisherLocation>New York</PublisherLocation>
  </PublisherInfo>
  <Journal>
    <JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered">
      <JournalID>12248</JournalID>
      <JournalElectronicISSN>1550-7416</JournalElectronicISSN>
      <JournalTitle>The AAPS Journal</JournalTitle>
      <JournalAbbreviatedTitle>AAPS J</JournalAbbreviatedTitle>
      <JournalSubjectGroup>
        <JournalSubject Code="F" Type="Primary">Pharmacy</JournalSubject>
        <JournalSubject Code="F00008" Priority="1" Type="Secondary">Pharmacy</JournalSubject>
        <JournalSubject Code="B21007" Priority="2" Type="Secondary">Pharmacology/Toxicology</JournalSubject>
        <JournalSubject Code="C12002" Priority="3" Type="Secondary">Biotechnology</JournalSubject>
      </JournalSubjectGroup>
    </JournalInfo>
    <Volume>
      <VolumeInfo TocLevels="0" VolumeType="Regular">
        <VolumeIDStart>7</VolumeIDStart>
        <VolumeIDEnd>7</VolumeIDEnd>
        <VolumeIssueCount>4</VolumeIssueCount>
      </VolumeInfo>
      <Issue IssueType="Regular">
        <IssueInfo TocLevels="0">
          <IssueIDStart>1</IssueIDStart>
          <IssueIDEnd>1</IssueIDEnd>
          <IssueArticleCount>25</IssueArticleCount>
          <IssueHistory>
            <CoverDate>
              <Year>2005</Year>
              <Month>3</Month>
            </CoverDate>
          </IssueHistory>
          <IssueCopyright>
            <CopyrightHolderName>American Association of Pharmaceutical Scientists</CopyrightHolderName>
            <CopyrightYear>2005</CopyrightYear>
          </IssueCopyright>
        </IssueInfo>
        <Article ID="Art7">
          <ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0">
            <ArticleID>71054</ArticleID>
            <ArticleDOI>10.1208/aapsj070107</ArticleDOI>
            <ArticleSequenceNumber>7</ArticleSequenceNumber>
            <ArticleTitle Language="En">New questions regarding bioequivalence of levothyroxine preparations: A Clinician's response</ArticleTitle>
            <ArticleFirstPage>E54</ArticleFirstPage>
            <ArticleLastPage>E58</ArticleLastPage>
            <ArticleHistory>
              <RegistrationDate>
                <Year>2008</Year>
                <Month>1</Month>
                <Day>28</Day>
              </RegistrationDate>
              <Received>
                <Year>2005</Year>
                <Month>2</Month>
                <Day>7</Day>
              </Received>
              <Accepted>
                <Year>2005</Year>
                <Month>2</Month>
                <Day>7</Day>
              </Accepted>
            </ArticleHistory>
            <ArticleCopyright>
              <CopyrightHolderName>American Association of Pharmaceutical Scientists</CopyrightHolderName>
              <CopyrightYear>2005</CopyrightYear>
            </ArticleCopyright>
            <ArticleGrants Type="Regular">
              <MetadataGrant Grant="OpenAccess"/>
              <AbstractGrant Grant="OpenAccess"/>
              <BodyPDFGrant Grant="Restricted"/>
              <BodyHTMLGrant Grant="Restricted"/>
              <BibliographyGrant Grant="Restricted"/>
              <ESMGrant Grant="Restricted"/>
            </ArticleGrants>
            <ArticleContext>
              <JournalID>12248</JournalID>
              <VolumeIDStart>7</VolumeIDStart>
              <VolumeIDEnd>7</VolumeIDEnd>
              <IssueIDStart>1</IssueIDStart>
              <IssueIDEnd>1</IssueIDEnd>
            </ArticleContext>
          </ArticleInfo>
          <ArticleHeader>
            <AuthorGroup>
              <Author AffiliationIDS="Aff1 Aff2" CorrespondingAffiliationID="Aff3">
                <AuthorName DisplayOrder="Western">
                  <GivenName>William</GivenName>
                  <GivenName>L.</GivenName>
                  <FamilyName>Green</FamilyName>
                </AuthorName>
                <Contact>
                  <Phone>(206) 533-6320</Phone>
                  <Fax>(413)254-9148</Fax>
                  <Email>annebillgreen@earthlink.net</Email>
                </Contact>
              </Author>
              <Affiliation ID="Aff1">
                <OrgDivision>Division of Endocrinology, Metabolism, and Nutrition</OrgDivision>
                <OrgName>VA Puget Sound Health Care System</OrgName>
                <OrgAddress>
                  <Postcode>98108</Postcode>
                  <City>Seattle</City>
                  <State>WA</State>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff2">
                <OrgName>University of Washington School of Medicine</OrgName>
                <OrgAddress>
                  <Postcode>98195</Postcode>
                  <City>Seattle</City>
                  <State>WA</State>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff3">
                <OrgAddress>
                  <Street>121 NW 171st Street</Street>
                  <Postcode>98177</Postcode>
                  <City>Shoreline</City>
                  <State>WA</State>
                </OrgAddress>
              </Affiliation>
            </AuthorGroup>
            <Abstract ID="Abs1" Language="En">
              <Heading>Abstract</Heading>
              <Para>A recent decision by the Food and Drug Administration (FDA) to declare various brands of levothyroxine bioequivalent has provoked objections from several physicians' organizations. These organization assert that the method of testing bioequivalence is flawed, and that indiscriminate switching among preparations could lead to serious instances of undertreatment and overtreatment of hypothyroid patients. In this review we first list common indications for thyroid hormone administration, distinguishing its use as replacement therapy in hypothyroidism from its use to suppress thyrotropin (TSH) secretion in cases of thyroid cancer, nodules, and goiter. The dangers associated with changing to a preparation with different biovailability are summarized, noting the particular danger of giving a more active preparation to a patient receiving TSH-suppressive doses of levothyroxine. However, these dangers are part of a larger problem: there are data showing that large numbers of patients are already receiving an improper dosage of levothyroxine, as judged from measurements of serum TSH. The recent history of FDA actions concerning levothyroxine bioequivalence and the arguments of those in disagreement are summarized. The immediate response to these problems should be better education of both patients and physicians. It is also recommended that there be further discussion of the problems in determining bioequivalence, and that consideration be given to more accurate and clinically relevant methods. Such methods should include assessment of the changes in TSH induced by each preparation in athyrotic patients.</Para>
            </Abstract>
            <ArticleNote Type="Misc">
              <SimplePara>Published: March 30, 2005</SimplePara>
            </ArticleNote>
          </ArticleHeader>
          <BodyRef FileRef="BodyRef/PDF/12248_2008_Article_71054.pdf" TargetType="OnlinePDF"/>
          <ArticleBackmatter>
            <Bibliography ID="Bib1">
              <Heading>References</Heading>
              <Citation ID="CR1">
                <CitationNumber>1.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JV</Initials>
                    <FamilyName>Hennessey</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Levothyroxine a new drug? Since when? How could that be?</ArticleTitle>
                  <JournalTitle>Thyroid</JournalTitle>
                  <VolumeID>13</VolumeID>
                  <FirstPage>279</FirstPage>
                  <LastPage>282</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12729477</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1089/105072503321582088</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Hennessey JV. Levothyroxine a new drug? Since when? How could that be?.<Emphasis Type="Italic">Thyroid</Emphasis> 2003;13:279–282.</BibUnstructured>
              </Citation>
              <Citation ID="CR2">
                <CitationNumber>2.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>SJ</Initials>
                    <FamilyName>Mandel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GA</Initials>
                    <FamilyName>Brent</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PR</Initials>
                    <FamilyName>Larsen</FamilyName>
                  </BibAuthorName>
                  <Year>1993</Year>
                  <ArticleTitle Language="En">Levothyroxine therapy in patients with thyroid disease</ArticleTitle>
                  <JournalTitle>Ann Intern Med.</JournalTitle>
                  <VolumeID>119</VolumeID>
                  <FirstPage>492</FirstPage>
                  <LastPage>502</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8357116</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK3szmt1yitw%3D%3D</Handle>
                  </Occurrence>
<Occurrence Type="DOI">
<Handle>10.7326/0003-4819-119-6-199309150-00009</Handle>
</Occurrence>
                </BibArticle>
                <BibUnstructured>Mandel SJ, Brent GA, Larsen PR. Levothyroxine therapy in patients with thyroid disease.<Emphasis Type="Italic">Ann Intern Med.</Emphasis> 1993;119:492–502.</BibUnstructured>
              </Citation>
              <Citation ID="CR3">
                <CitationNumber>3.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>PA</Initials>
                    <FamilyName>Singer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DS</Initials>
                    <FamilyName>Cooper</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>EG</Initials>
                    <FamilyName>Levy</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1995</Year>
                  <ArticleTitle Language="En">Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association</ArticleTitle>
                  <JournalTitle>JAMA</JournalTitle>
                  <VolumeID>273</VolumeID>
                  <FirstPage>808</FirstPage>
                  <LastPage>812</LastPage>
                  <Occurrence Type="PID">
                    <Handle>7532241</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1001/jama.273.10.808</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK2M7msFGqtQ%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Singer PA, Cooper DS, Levy EG et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association.<Emphasis Type="Italic">JAMA</Emphasis>. 1995;273:808–812.</BibUnstructured>
              </Citation>
              <Citation ID="CR4">
                <CitationNumber>4.</CitationNumber>
                <BibArticle>
                  <InstitutionalAuthorName>AACE Thyroid Task Force</InstitutionalAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">American Association of Clinical endorrinologist medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism</ArticleTitle>
                  <JournalTitle>Endocr Pract.</JournalTitle>
                  <VolumeID>8</VolumeID>
                  <FirstPage>457</FirstPage>
                  <LastPage>469</LastPage>
                </BibArticle>
                <BibUnstructured>AACE Thyroid Task Force. American Association of Clinical endorrinologist medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism.<Emphasis Type="Italic">Endocr Pract.</Emphasis> 2002;8:457–469.</BibUnstructured>
              </Citation>
              <Citation ID="CR5">
                <CitationNumber>5.</CitationNumber>
                <BibUnstructured>McDermott MT. American College of Physicians, Physicians' Information and Education Resource: Hypothyroidism. Available at: http://pier.acponline. org/physicians/diseases/d238/d238.html.Accessed September 20, 2004.</BibUnstructured>
              </Citation>
              <Citation ID="CR6">
                <CitationNumber>6.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>VJ</Initials>
                    <FamilyName>Pop</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JL</Initials>
                    <FamilyName>Kuijpens</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AL</Initials>
                    <FamilyName>Baar</FamilyName>
                    <Particle>van</Particle>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Low maternal free thyroxine concentrations during early pregnancy are associated with impaired psychomotor development in infancy</ArticleTitle>
                  <JournalTitle>Clin Endocrinol (Oxf)</JournalTitle>
                  <VolumeID>50</VolumeID>
                  <FirstPage>149</FirstPage>
                  <LastPage>155</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1046/j.1365-2265.1999.00639.x</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK1MzisVKktQ%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Pop VJ, Kuijpens JL, van Baar AL, et al. Low maternal free thyroxine concentrations during early pregnancy are associated with impaired psychomotor development in infancy.<Emphasis Type="Italic">Clin Endocrinol (Oxf)</Emphasis>. 1999;50:149–155.</BibUnstructured>
              </Citation>
              <Citation ID="CR7">
                <CitationNumber>7.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JE</Initials>
                    <FamilyName>Haddow</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GE</Initials>
                    <FamilyName>Palomaki</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>WC</Initials>
                    <FamilyName>Allan</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Maternal thyroid dificiency during pregnancy and subsequent neuropsychological development of the child</ArticleTitle>
                  <JournalTitle>N Engl J Med.</JournalTitle>
                  <VolumeID>341</VolumeID>
                  <FirstPage>549</FirstPage>
                  <LastPage>555</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10451459</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1056/NEJM199908193410801</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK1Mzmt1Whsg%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Haddow JE, Palomaki GE, Allan WC, et al. Maternal thyroid dificiency during pregnancy and subsequent neuropsychological development of the child.<Emphasis Type="Italic">N Engl J Med.</Emphasis> 1999;341:549–555.</BibUnstructured>
              </Citation>
              <Citation ID="CR8">
                <CitationNumber>8.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>EK</Initials>
                    <FamilyName>Alexander</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Marqusee</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Lawrence</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Jarolim</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GA</Initials>
                    <FamilyName>Fischer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PR</Initials>
                    <FamilyName>Larsen</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidims</ArticleTitle>
                  <JournalTitle>N Engl J Med.</JournalTitle>
                  <VolumeID>351</VolumeID>
                  <FirstPage>241</FirstPage>
                  <LastPage>249</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15254282</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1056/NEJMoa040079</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXlslKku7k%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Alexander EK, Marqusee E, Lawrence J, Jarolim P, Fischer GA, Larsen PR. Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidims.<Emphasis Type="Italic">N Engl J Med.</Emphasis> 2004;351:241–249.</BibUnstructured>
              </Citation>
              <Citation ID="CR9">
                <CitationNumber>9.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>Z</Initials>
                    <FamilyName>Baloch</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Carayon</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Conte-Devolx</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease</ArticleTitle>
                  <JournalTitle>Thyroid.</JournalTitle>
                  <VolumeID>13</VolumeID>
                  <FirstPage>3</FirstPage>
                  <LastPage>126</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12625976</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1089/105072503321086962</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Baloch Z, Carayon P, Conte-Devolx B, et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease.<Emphasis Type="Italic">Thyroid.</Emphasis> 2003;13:3–126.</BibUnstructured>
              </Citation>
              <Citation ID="CR10">
                <CitationNumber>10.</CitationNumber>
                <BibBook>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Arem</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <BookTitle>The Thyroid Solution</BookTitle>
                  <PublisherName>Ballantine Books</PublisherName>
                  <PublisherLocation>New York, NY</PublisherLocation>
                </BibBook>
                <BibUnstructured>Arem R.<Emphasis Type="Italic">The Thyroid Solution</Emphasis>. New York, NY: Ballantine Books; 1999.</BibUnstructured>
              </Citation>
              <Citation ID="CR11">
                <CitationNumber>11.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Bunevicius</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Kazanavicius</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Zalinkevicius</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AJ</Initials>
                    <FamilyName>Prange</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism</ArticleTitle>
                  <JournalTitle>N Engl J Med.</JournalTitle>
                  <VolumeID>340</VolumeID>
                  <FirstPage>424</FirstPage>
                  <LastPage>429</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9971866</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1056/NEJM199902113400603</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1MXhtlSiur4%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bunevicius R, Kazanavicius G, Zalinkevicius R, Prange AJ, Jr. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism.<Emphasis Type="Italic">N Engl J Med.</Emphasis> 1999;340:424–429.</BibUnstructured>
              </Citation>
              <Citation ID="CR12">
                <CitationNumber>12.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>AM</Initials>
                    <FamilyName>Sawka</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HC</Initials>
                    <FamilyName>Gerstein</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MJ</Initials>
                    <FamilyName>Marriott</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GM</Initials>
                    <FamilyName>MacQueen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RT</Initials>
                    <FamilyName>Joffe</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Does a combination regiment of thyroxine (T4) and 3,5,3?-triiodothyronine improve depressive symptoms better than T4 alone in patients with hypothyroidism? Results of a double-blind, randomized, controlled trial</ArticleTitle>
                  <JournalTitle>J Clin Endocrinol Metab.</JournalTitle>
                  <VolumeID>88</VolumeID>
                  <FirstPage>4551</FirstPage>
                  <LastPage>4555</LastPage>
                  <Occurrence Type="PID">
                    <Handle>14557420</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1210/jc.2003-030139</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXoslemsLk%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Sawka AM, Gerstein HC, Marriott MJ, MacQueen GM, Joffe RT. Does a combination regiment of thyroxine (T4) and 3,5,3?-triiodothyronine improve depressive symptoms better than T4 alone in patients with hypothyroidism? Results of a double-blind, randomized, controlled trial.<Emphasis Type="Italic">J Clin Endocrinol Metab.</Emphasis> 2003;88:4551–4555.</BibUnstructured>
              </Citation>
              <Citation ID="CR13">
                <CitationNumber>13.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>PW</Initials>
                    <FamilyName>Clyde</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AE</Initials>
                    <FamilyName>Harari</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>EJ</Initials>
                    <FamilyName>Getka</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KM</Initials>
                    <FamilyName>Shakir</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial</ArticleTitle>
                  <JournalTitle>JAMA.</JournalTitle>
                  <VolumeID>290</VolumeID>
                  <FirstPage>2952</FirstPage>
                  <LastPage>2958</LastPage>
                  <Occurrence Type="PID">
                    <Handle>14665656</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1001/jama.290.22.2952</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXpvVKhtbw%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial.<Emphasis Type="Italic">JAMA.</Emphasis> 2003;290:2952–2958.</BibUnstructured>
              </Citation>
              <Citation ID="CR14">
                <CitationNumber>14.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JP</Initials>
                    <FamilyName>Walsh</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Shiels</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>EM</Initials>
                    <FamilyName>Lim</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Combined thyroxine/liothyronine treatment does not improve well-being, quality of life, or cognitive function compared to thyroxine alone: a randomized controlled trial in patients with primary hypothyroidism</ArticleTitle>
                  <JournalTitle>J Clin Endocrinol Metab.</JournalTitle>
                  <VolumeID>88</VolumeID>
                  <FirstPage>4543</FirstPage>
                  <LastPage>4550</LastPage>
                  <Occurrence Type="PID">
                    <Handle>14557419</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1210/jc.2003-030249</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXoslemsLg%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Walsh JP, Shiels L, Lim EM, et al. Combined thyroxine/liothyronine treatment does not improve well-being, quality of life, or cognitive function compared to thyroxine alone: a randomized controlled trial in patients with primary hypothyroidism.<Emphasis Type="Italic">J Clin Endocrinol Metab.</Emphasis> 2003;88:4543–4550.</BibUnstructured>
              </Citation>
              <Citation ID="CR15">
                <CitationNumber>15.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>I</Initials>
                    <FamilyName>Shimon</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>O</Initials>
                    <FamilyName>Cohen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Lubetsky</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Olchovsky</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Thyrotropin suppression by thyroid hormone replacement is correlated with thyroxine level normalization in central hypothyroidism</ArticleTitle>
                  <JournalTitle>Thyroid.</JournalTitle>
                  <VolumeID>12</VolumeID>
                  <FirstPage>823</FirstPage>
                  <LastPage>827</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12481949</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1089/105072502760339406</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38Xot1Ggtrs%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Shimon I, Cohen O, Lubetsky A, Olchovsky D. Thyrotropin suppression by thyroid hormone replacement is correlated with thyroxine level normalization in central hypothyroidism.<Emphasis Type="Italic">Thyroid.</Emphasis> 2002;12:823–827.</BibUnstructured>
              </Citation>
              <Citation ID="CR16">
                <CitationNumber>16.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>NJ</Initials>
                    <FamilyName>McGriff</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Csako</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Gourgiotis</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CG</Initials>
                    <FamilyName>Lori</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Pucino</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>NJ</Initials>
                    <FamilyName>Sarlis</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Effects of thyroid hormone suppression therapy on adverse clinical out-comes in thyroid cancer</ArticleTitle>
                  <JournalTitle>Ann Med.</JournalTitle>
                  <VolumeID>34</VolumeID>
                  <FirstPage>554</FirstPage>
                  <LastPage>564</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12553495</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1080/078538902321117760</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXhs1Wgtbc%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>McGriff NJ, Csako G, Gourgiotis L, Lori CG, Pucino F, Sarlis NJ. Effects of thyroid hormone suppression therapy on adverse clinical out-comes in thyroid cancer.<Emphasis Type="Italic">Ann Med.</Emphasis> 2002;34:554–564.</BibUnstructured>
              </Citation>
              <Citation ID="CR17">
                <CitationNumber>17.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Carr</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DT</Initials>
                    <FamilyName>McLeod</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Parry</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HM</Initials>
                    <FamilyName>Thornes</FamilyName>
                  </BibAuthorName>
                  <Year>1988</Year>
                  <ArticleTitle Language="En">Fine adjustment of thyroxine replacement dosage: comparison of the thyrotrophin releasing hormone test using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment</ArticleTitle>
                  <JournalTitle>Clin Endocrinol (Oxf).</JournalTitle>
                  <VolumeID>28</VolumeID>
                  <FirstPage>325</FirstPage>
                  <LastPage>333</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1111/j.1365-2265.1988.tb01219.x</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaL1M%2FgtlKruw%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Carr D, McLeod DT, Parry G, Thornes HM. Fine adjustment of thyroxine replacement dosage: comparison of the thyrotrophin releasing hormone test using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment.<Emphasis Type="Italic">Clin Endocrinol (Oxf).</Emphasis> 1988;28:325–333.</BibUnstructured>
              </Citation>
              <Citation ID="CR18">
                <CitationNumber>18.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>SM</Initials>
                    <FamilyName>Lum</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JT</Initials>
                    <FamilyName>Nicoloff</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CA</Initials>
                    <FamilyName>Spencer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>EM</Initials>
                    <FamilyName>Kaptein</FamilyName>
                  </BibAuthorName>
                  <Year>1984</Year>
                  <ArticleTitle Language="En">Peripheral tissue mechanism for maintenance of serum triiodothyronine values in a thyroxine-deficient state in man</ArticleTitle>
                  <JournalTitle>J Clin Invest.</JournalTitle>
                  <VolumeID>73</VolumeID>
                  <FirstPage>570</FirstPage>
                  <LastPage>575</LastPage>
                  <Occurrence Type="PID">
                    <Handle>6699177</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1172/JCI111245</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL2cXhtFyrurY%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Lum SM, Nicoloff JT, Spencer CA, Kaptein EM. Peripheral tissue mechanism for maintenance of serum triiodothyronine values in a thyroxine-deficient state in man.<Emphasis Type="Italic">J Clin Invest.</Emphasis> 1984;73:570–575.</BibUnstructured>
              </Citation>
              <Citation ID="CR19">
                <CitationNumber>19.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JT</Initials>
                    <FamilyName>Nicoloff</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SM</Initials>
                    <FamilyName>Lum</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CA</Initials>
                    <FamilyName>Spencer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Morris</FamilyName>
                  </BibAuthorName>
                  <Year>1984</Year>
                  <ArticleTitle Language="En">Peripheral autoregulation of thyroxine to triiodothyronine conversion in man</ArticleTitle>
                  <JournalTitle>Horm Metab Res Suppl.</JournalTitle>
                  <VolumeID>14</VolumeID>
                  <FirstPage>74</FirstPage>
                  <LastPage>79</LastPage>
                  <Occurrence Type="PID">
                    <Handle>6595193</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL2MXptVCisw%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Nicoloff JT, Lum SM, Spencer CA, Morris R. Peripheral autoregulation of thyroxine to triiodothyronine conversion in man.<Emphasis Type="Italic">Horm Metab Res Suppl.</Emphasis> 1984;14:74–79.</BibUnstructured>
              </Citation>
              <Citation ID="CR20">
                <CitationNumber>20.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>CT</Initials>
                    <FamilyName>Sawin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Geller</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PA</Initials>
                    <FamilyName>Wolf</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1994</Year>
                  <ArticleTitle Language="En">Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons</ArticleTitle>
                  <JournalTitle>N Engl J Med.</JournalTitle>
                  <VolumeID>331</VolumeID>
                  <FirstPage>1249</FirstPage>
                  <LastPage>1252</LastPage>
                  <Occurrence Type="PID">
                    <Handle>7935681</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1056/NEJM199411103311901</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK2M%2FitFGqsg%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons.<Emphasis Type="Italic">N Engl J Med.</Emphasis> 1994;331:1249–1252.</BibUnstructured>
              </Citation>
              <Citation ID="CR21">
                <CitationNumber>21.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Biondi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Fazio</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Carella</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1993</Year>
                  <ArticleTitle Language="En">Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine</ArticleTitle>
                  <JournalTitle>J Clin Endocrinol Metab.</JournalTitle>
                  <VolumeID>77</VolumeID>
                  <FirstPage>334</FirstPage>
                  <LastPage>338</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8345037</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1210/jc.77.2.334</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK3szks1GnsA%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Biondi B, Fazio S, Carella C. et al. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine.<Emphasis Type="Italic">J Clin Endocrinol Metab.</Emphasis> 1993;77:334–338.</BibUnstructured>
              </Citation>
              <Citation ID="CR22">
                <CitationNumber>22.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Mercuro</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MG</Initials>
                    <FamilyName>Panzuto</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Bina</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring</ArticleTitle>
                  <JournalTitle>J Clin Endocrinol Metab.</JournalTitle>
                  <VolumeID>85</VolumeID>
                  <FirstPage>159</FirstPage>
                  <LastPage>164</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10634380</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1210/jc.85.1.159</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXjtl2gsA%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Mercuro G, Panzuto MG, Bina A, et al. Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring.<Emphasis Type="Italic">J Clin Endocrinol Metab.</Emphasis> 2000;85:159–164.</BibUnstructured>
              </Citation>
              <Citation ID="CR23">
                <CitationNumber>23.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>SL</Initials>
                    <FamilyName>Greenspan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>FS</Initials>
                    <FamilyName>Greenspan</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">The effect of thyroid hormone on skeletal integrity</ArticleTitle>
                  <JournalTitle>Ann Intern Med.</JournalTitle>
                  <VolumeID>130</VolumeID>
                  <FirstPage>750</FirstPage>
                  <LastPage>758</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10357695</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1MXjtVGjtr0%3D</Handle>
                  </Occurrence>
<Occurrence Type="DOI">
<Handle>10.7326/0003-4819-130-9-199905040-00016</Handle>
</Occurrence>
                </BibArticle>
                <BibUnstructured>Greenspan SL, Greenspan FS. The effect of thyroid hormone on skeletal integrity.<Emphasis Type="Italic">Ann Intern Med.</Emphasis> 1999;130:750–758.</BibUnstructured>
              </Citation>
              <Citation ID="CR24">
                <CitationNumber>24.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>DS</Initials>
                    <FamilyName>Ross</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RM</Initials>
                    <FamilyName>Neer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>EC</Initials>
                    <FamilyName>Ridgway</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GH</Initials>
                    <FamilyName>Daniels</FamilyName>
                  </BibAuthorName>
                  <Year>1987</Year>
                  <ArticleTitle Language="En">Subclinical hyperthyroidism and reduced bone density as a possible results of prolonged suppression of the pituitary-thyroid axis with L-thyroxine</ArticleTitle>
                  <JournalTitle>Am J Med.</JournalTitle>
                  <VolumeID>82</VolumeID>
                  <FirstPage>1167</FirstPage>
                  <LastPage>1170</LastPage>
                  <Occurrence Type="PID">
                    <Handle>3605133</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0002-9343(87)90219-1</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaL2s3mslKksg%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Ross DS, Neer RM, Ridgway EC, Daniels GH. Subclinical hyperthyroidism and reduced bone density as a possible results of prolonged suppression of the pituitary-thyroid axis with L-thyroxine.<Emphasis Type="Italic">Am J Med.</Emphasis> 1987;82:1167–1170.</BibUnstructured>
              </Citation>
              <Citation ID="CR25">
                <CitationNumber>25.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>AD</Initials>
                    <FamilyName>Toft</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Clinical practice. Subclinical hyperthyroidism</ArticleTitle>
                  <JournalTitle>N Engl J Med.</JournalTitle>
                  <VolumeID>345</VolumeID>
                  <FirstPage>512</FirstPage>
                  <LastPage>516</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11519506</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1056/NEJMcp010145</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD3Mvns1SqsQ%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Toft AD. Clinical practice. Subclinical hyperthyroidism.<Emphasis Type="Italic">N Engl J Med.</Emphasis> 2001;345:512–516.</BibUnstructured>
              </Citation>
              <Citation ID="CR26">
                <CitationNumber>26.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>BL</Initials>
                    <FamilyName>Solomon</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Wartofsky</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KD</Initials>
                    <FamilyName>Burman</FamilyName>
                  </BibAuthorName>
                  <Year>1993</Year>
                  <ArticleTitle Language="En">Prevalence of fractures in postmenopausal women with thyroid disease</ArticleTitle>
                  <JournalTitle>Thyroid.</JournalTitle>
                  <VolumeID>3</VolumeID>
                  <FirstPage>17</FirstPage>
                  <LastPage>23</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8499760</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK3s3ntFKrtg%3D%3D</Handle>
                  </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1089/thy.1993.3.17</Handle>
</Occurrence>
                </BibArticle>
                <BibUnstructured>Solomon BL, Wartofsky L, Burman KD. Prevalence of fractures in postmenopausal women with thyroid disease.<Emphasis Type="Italic">Thyroid.</Emphasis> 1993;3:17–23.</BibUnstructured>
              </Citation>
              <Citation ID="CR27">
                <CitationNumber>27.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>DC</Initials>
                    <FamilyName>Bauer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Ettinger</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MC</Initials>
                    <FamilyName>Nevitt</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KL</Initials>
                    <FamilyName>Stone</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Risk for fracture in women with low serum levels of thyroid-stimulating hormone</ArticleTitle>
                  <JournalTitle>Ann Intern Med.</JournalTitle>
                  <VolumeID>134</VolumeID>
                  <FirstPage>561</FirstPage>
                  <LastPage>568</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12803168</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXivVaju7c%3D</Handle>
                  </Occurrence>
<Occurrence Type="DOI">
<Handle>10.7326/0003-4819-134-7-200104030-00009</Handle>
</Occurrence>
                </BibArticle>
                <BibUnstructured>Bauer DC, Ettinger B, Nevitt MC, Stone KL. Risk for fracture in women with low serum levels of thyroid-stimulating hormone.<Emphasis Type="Italic">Ann Intern Med.</Emphasis> 2001;134:561–568.</BibUnstructured>
              </Citation>
              <Citation ID="CR28">
                <CitationNumber>28.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>AE</Initials>
                    <FamilyName>Hak</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HA</Initials>
                    <FamilyName>Pols</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TJ</Initials>
                    <FamilyName>Visser</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HA</Initials>
                    <FamilyName>Drexhage</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Hofman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JC</Initials>
                    <FamilyName>Witteman</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study</ArticleTitle>
                  <JournalTitle>Ann Intern Med.</JournalTitle>
                  <VolumeID>132</VolumeID>
                  <FirstPage>270</FirstPage>
                  <LastPage>278</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10681281</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD3c7jt1egsg%3D%3D</Handle>
                  </Occurrence>
<Occurrence Type="DOI">
<Handle>10.7326/0003-4819-132-4-200002150-00004</Handle>
</Occurrence>
                </BibArticle>
                <BibUnstructured>Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study.<Emphasis Type="Italic">Ann Intern Med.</Emphasis> 2000;132:270–278.</BibUnstructured>
              </Citation>
              <Citation ID="CR29">
                <CitationNumber>29.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>WM</Initials>
                    <FamilyName>Tunbridge</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DC</Initials>
                    <FamilyName>Evered</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Hall</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1977</Year>
                  <ArticleTitle Language="En">Lipid profiles and cardiovascular disease in the Whickham area with particular reference to thyroid failure</ArticleTitle>
                  <JournalTitle>Clin Endocrinol (Oxf).</JournalTitle>
                  <VolumeID>7</VolumeID>
                  <FirstPage>495</FirstPage>
                  <LastPage>508</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1111/j.1365-2265.1977.tb01341.x</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaE1c%2Fot1Ogsw%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Tunbridge WM, Evered DC, Hall R, et al. Lipid profiles and cardiovascular disease in the Whickham area with particular reference to thyroid failure.<Emphasis Type="Italic">Clin Endocrinol (Oxf).</Emphasis> 1977;7:495–508.</BibUnstructured>
              </Citation>
              <Citation ID="CR30">
                <CitationNumber>30.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>GJ</Initials>
                    <FamilyName>Canaris</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>NR</Initials>
                    <FamilyName>Manowitz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Mayor</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>EC</Initials>
                    <FamilyName>Ridgway</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">The Colorado thyroid disease prevalence study</ArticleTitle>
                  <JournalTitle>Arch Intern Med.</JournalTitle>
                  <VolumeID>160</VolumeID>
                  <FirstPage>526</FirstPage>
                  <LastPage>534</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10695693</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1001/archinte.160.4.526</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD3c7lvVansg%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study.<Emphasis Type="Italic">Arch Intern Med.</Emphasis> 2000;160:526–534.</BibUnstructured>
              </Citation>
              <Citation ID="CR31">
                <CitationNumber>31.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JG</Initials>
                    <FamilyName>Hollowell</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>NW</Initials>
                    <FamilyName>Staehling</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>WD</Initials>
                    <FamilyName>Flanders</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994) National Health and Nutrition Examination Survey (NHANES III)</ArticleTitle>
                  <JournalTitle>J Clin Endocrinol Metab.</JournalTitle>
                  <VolumeID>87</VolumeID>
                  <FirstPage>489</FirstPage>
                  <LastPage>499</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11836274</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1210/jc.87.2.489</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XhsVSjtbw%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994) National Health and Nutrition Examination Survey (NHANES III).<Emphasis Type="Italic">J Clin Endocrinol Metab.</Emphasis> 2002;87:489–499.</BibUnstructured>
              </Citation>
              <Citation ID="CR32">
                <CitationNumber>32.</CitationNumber>
                <BibUnstructured>Food and Drug Administration. Center for Drug Evaluation and Research. Guidance for Industry: Levothyroxine Sodium Tablets—In Vivo Pharmacokinetic and Bioavailability Studies and In Vitro Dissolution Testing. Available at: http://www.fda.gov/cder/guidance/364 fnl.htm. Accessed March 8, 2000.</BibUnstructured>
              </Citation>
              <Citation ID="CR33">
                <CitationNumber>33.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>V</Initials>
                    <FamilyName>Blakesley</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W</Initials>
                    <FamilyName>Awni</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Locke</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Ludden</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GR</Initials>
                    <FamilyName>Granneman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>LE</Initials>
                    <FamilyName>Braverman</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Are bioequivalence studies of levothyroxine sodium formulations in euthyroid volunteers reliable?</ArticleTitle>
                  <JournalTitle>Thyroid.</JournalTitle>
                  <VolumeID>14</VolumeID>
                  <FirstPage>191</FirstPage>
                  <LastPage>200</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15072701</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1089/105072504773297867</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXisVWgtL4%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Blakesley V, Awni W, Locke C, Ludden T, Granneman GR, Braverman LE. Are bioequivalence studies of levothyroxine sodium formulations in euthyroid volunteers reliable?<Emphasis Type="Italic">Thyroid.</Emphasis> 2004;14:191–200.</BibUnstructured>
              </Citation>
              <Citation ID="CR34">
                <CitationNumber>34.</CitationNumber>
                <BibUnstructured>Yu LX. Letter to ANDA file: Approval of ANDA 76–187, Mylan Pharmaceuticals Inc, Levothyroxine Sodium Tablets. Available at: http://www.fda.gov/cder/foi/anda/2002/076187_Bioequiv_Corresp.pdf. Accessed June 5, 2002.</BibUnstructured>
              </Citation>
              <Citation ID="CR35">
                <CitationNumber>35.</CitationNumber>
                <BibUnstructured>Food and Drug Administration. Advisory Committe for Pharmaceutical Science. Record of Proceedings. Available at: http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3926T2.pdf. Accessed November 15, 2004.</BibUnstructured>
              </Citation>
              <Citation ID="CR36">
                <CitationNumber>36.</CitationNumber>
                <BibUnstructured>Hubbard WK. Request that the Commissioner of Food and Drug take action described methodology for oral levothyroxine sodium drug products: Reply to Petitioners. Available at: http://www.fda.gov/ohrms/dockets/ dailys/04/June04/062904/03p-0387-pdn0001-vol5.pdf.Accessed June 23, 2004.</BibUnstructured>
              </Citation>
              <Citation ID="CR37">
                <CitationNumber>37.</CitationNumber>
                <BibArticle>
                  <InstitutionalAuthorName>American Thyroid Association, The Endocrine Society, American Association of Clinical Endocrinologists</InstitutionalAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Joint statement on the U.S. Food and Drug Administration's decision regarding bioequivalence of levothyroxine sodium</ArticleTitle>
                  <JournalTitle>Thyroid.</JournalTitle>
                  <VolumeID>14</VolumeID>
                  <FirstPage>486</FirstPage>
                  <LastPage>486</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1089/1050725041517138</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>American Thyroid Association, The Endocrine Society, American Association of Clinical Endocrinologists. Joint statement on the U.S. Food and Drug Administration's decision regarding bioequivalence of levothyroxine sodium.<Emphasis Type="Italic">Thyroid.</Emphasis> 2004;14:486.</BibUnstructured>
              </Citation>
              <Citation ID="CR38">
                <CitationNumber>38.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>LA</Initials>
                    <FamilyName>Burmeister</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MO</Initials>
                    <FamilyName>Goumaz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CN</Initials>
                    <FamilyName>Mariash</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JH</Initials>
                    <FamilyName>Oppenheimer</FamilyName>
                  </BibAuthorName>
                  <Year>1992</Year>
                  <ArticleTitle Language="En">Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer</ArticleTitle>
                  <JournalTitle>J Clin Endocrinol Metab.</JournalTitle>
                  <VolumeID>75</VolumeID>
                  <FirstPage>344</FirstPage>
                  <LastPage>350</LastPage>
                  <Occurrence Type="PID">
                    <Handle>1639933</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1210/jc.75.2.344</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK38zkvVKitw%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Burmeister LA, Goumaz MO, Mariash CN, Oppenheimer JH. Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer.<Emphasis Type="Italic">J Clin Endocrinol Metab.</Emphasis> 1992;75:344–350.</BibUnstructured>
              </Citation>
              <Citation ID="CR39">
                <CitationNumber>39.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JH</Initials>
                    <FamilyName>Oppenheimer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>LE</Initials>
                    <FamilyName>Braverman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Toft</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>IM</Initials>
                    <FamilyName>Jackson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PW</Initials>
                    <FamilyName>Ladenson</FamilyName>
                  </BibAuthorName>
                  <Year>1995</Year>
                  <ArticleTitle Language="En">A therapeutic controversy. Thyroid hormone treatment when and what?</ArticleTitle>
                  <JournalTitle>J Clin Endocrinol Metab.</JournalTitle>
                  <VolumeID>80</VolumeID>
                  <FirstPage>2873</FirstPage>
                  <LastPage>2883</LastPage>
                  <Occurrence Type="PID">
                    <Handle>7559868</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1210/jc.80.10.2873</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2MXoslCns74%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Oppenheimer JH, Braverman LE, Toft A, Jackson IM, Ladenson PW. A therapeutic controversy. Thyroid hormone treatment when and what?<Emphasis Type="Italic">J Clin Endocrinol Metab.</Emphasis> 1995;80:2873–2883.</BibUnstructured>
              </Citation>
            </Bibliography>
          </ArticleBackmatter>
        </Article>
      </Issue>
    </Volume>
  </Journal>
</Publisher>
